Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer

Clinical Observation of Erlotinib in the Treatment of Advanced and Previously Treated Non-small Cell Lung Cancer

Background and objective Erlotinib is a small molecular inhibitor of tyrosine kinase. One study has confirmed that it can prolong the median progression-free survival time (PFS), and can improve the one-year survival rate of patients with advanced non-small cell lung cancer. The aim of this trial is...

Full description

Bibliographic Details
Main Authors: Liyan XU, Yuhua WU, Mingzhi LI, Heling SHI, Qiyi MENG, Zan LIU, Wei WU, Zhe LIU, Junfang TANG, Yunzhong ZHU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2009-12-01
Series:Chinese Journal of Lung Cancer
Subjects:
Erlotinib
Lung neoplasms
Targeted therapy
Therapeutic effect
Prognosis
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.10&path[]=1234

Internet

http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path[]=10.3779%2Fj.issn.1009-3419.2009.12.10&path[]=1234

Similar Items